nodes	percent_of_prediction	percent_of_DWPC	metapath
Metolazone—CA9—cervical cancer	0.929	1	CbGaD
Metolazone—CA5A—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00937	0.216	CbGpPWpGaD
Metolazone—CA7—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00875	0.201	CbGpPWpGaD
Metolazone—CA5B—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00875	0.201	CbGpPWpGaD
Metolazone—CA12—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00811	0.186	CbGpPWpGaD
Metolazone—CA4—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00647	0.149	CbGpPWpGaD
Metolazone—Benzthiazide—CA9—cervical cancer	0.00239	0.351	CrCbGaD
Metolazone—Indapamide—CA9—cervical cancer	0.00237	0.349	CrCbGaD
Metolazone—CA5A—female reproductive system—cervical cancer	0.00235	0.138	CbGeAlD
Metolazone—Chlorthalidone—CA9—cervical cancer	0.00204	0.3	CrCbGaD
Metolazone—CA7—renal system—cervical cancer	0.00195	0.114	CbGeAlD
Metolazone—SLC12A3—renal system—cervical cancer	0.00191	0.112	CbGeAlD
Metolazone—SLC12A3—female reproductive system—cervical cancer	0.00153	0.0896	CbGeAlD
Metolazone—CA9—female reproductive system—cervical cancer	0.00137	0.0803	CbGeAlD
Metolazone—CA12—renal system—cervical cancer	0.00127	0.0742	CbGeAlD
Metolazone—CA5B—mammalian vulva—cervical cancer	0.00106	0.0622	CbGeAlD
Metolazone—CA12—female reproductive system—cervical cancer	0.00101	0.0594	CbGeAlD
Metolazone—CA5B—female reproductive system—cervical cancer	0.00091	0.0533	CbGeAlD
Metolazone—CA5B—vagina—cervical cancer	0.000823	0.0482	CbGeAlD
Metolazone—CA4—renal system—cervical cancer	0.000785	0.0459	CbGeAlD
Metolazone—CA4—female reproductive system—cervical cancer	0.000628	0.0368	CbGeAlD
Metolazone—CA4—female gonad—cervical cancer	0.000572	0.0335	CbGeAlD
Metolazone—CA9—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000541	0.0124	CbGpPWpGaD
Metolazone—CA5B—lymph node—cervical cancer	0.000533	0.0312	CbGeAlD
Metolazone—CA4—lymph node—cervical cancer	0.000368	0.0215	CbGeAlD
Metolazone—Neuropathy—Topotecan—cervical cancer	0.000241	0.0662	CcSEcCtD
Metolazone—CA5A—Metabolism—CA9—cervical cancer	0.00019	0.00438	CbGpPWpGaD
Metolazone—Lethargy—Topotecan—cervical cancer	0.00019	0.0522	CcSEcCtD
Metolazone—CA7—Metabolism—CA9—cervical cancer	0.000178	0.00409	CbGpPWpGaD
Metolazone—CA5B—Metabolism—CA9—cervical cancer	0.000178	0.00409	CbGpPWpGaD
Metolazone—Cramp muscle—Topotecan—cervical cancer	0.000168	0.0461	CcSEcCtD
Metolazone—CA12—Metabolism—CA9—cervical cancer	0.000165	0.00379	CbGpPWpGaD
Metolazone—Neuropathy peripheral—Topotecan—cervical cancer	0.000141	0.0387	CcSEcCtD
Metolazone—Epistaxis—Topotecan—cervical cancer	0.000136	0.0372	CcSEcCtD
Metolazone—CA4—Metabolism—CA9—cervical cancer	0.000131	0.00302	CbGpPWpGaD
Metolazone—Chills—Topotecan—cervical cancer	0.000116	0.0318	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—MTOR—cervical cancer	0.000115	0.00265	CbGpPWpGaD
Metolazone—Back pain—Topotecan—cervical cancer	0.000109	0.0298	CcSEcCtD
Metolazone—Muscle spasms—Topotecan—cervical cancer	0.000108	0.0296	CcSEcCtD
Metolazone—Ill-defined disorder—Topotecan—cervical cancer	0.000104	0.0286	CcSEcCtD
Metolazone—Anaemia—Topotecan—cervical cancer	0.000104	0.0285	CcSEcCtD
Metolazone—Malaise—Topotecan—cervical cancer	0.000101	0.0278	CcSEcCtD
Metolazone—Leukopenia—Topotecan—cervical cancer	0.000101	0.0276	CcSEcCtD
Metolazone—Cough—Topotecan—cervical cancer	9.8e-05	0.0269	CcSEcCtD
Metolazone—Arthralgia—Topotecan—cervical cancer	9.56e-05	0.0262	CcSEcCtD
Metolazone—Chest pain—Topotecan—cervical cancer	9.56e-05	0.0262	CcSEcCtD
Metolazone—Discomfort—Topotecan—cervical cancer	9.45e-05	0.0259	CcSEcCtD
Metolazone—Thrombocytopenia—Topotecan—cervical cancer	8.98e-05	0.0246	CcSEcCtD
Metolazone—CA9—Cellular responses to stress—STAT3—cervical cancer	8.9e-05	0.00205	CbGpPWpGaD
Metolazone—Anorexia—Topotecan—cervical cancer	8.74e-05	0.024	CcSEcCtD
Metolazone—Musculoskeletal discomfort—Topotecan—cervical cancer	8.35e-05	0.0229	CcSEcCtD
Metolazone—Paraesthesia—Topotecan—cervical cancer	8.23e-05	0.0226	CcSEcCtD
Metolazone—Dyspepsia—Topotecan—cervical cancer	8.07e-05	0.0221	CcSEcCtD
Metolazone—Decreased appetite—Topotecan—cervical cancer	7.97e-05	0.0219	CcSEcCtD
Metolazone—Fatigue—Topotecan—cervical cancer	7.9e-05	0.0217	CcSEcCtD
Metolazone—Pain—Topotecan—cervical cancer	7.84e-05	0.0215	CcSEcCtD
Metolazone—Constipation—Topotecan—cervical cancer	7.84e-05	0.0215	CcSEcCtD
Metolazone—CA5A—Metabolism—MTHFR—cervical cancer	7.73e-05	0.00178	CbGpPWpGaD
Metolazone—Feeling abnormal—Topotecan—cervical cancer	7.55e-05	0.0207	CcSEcCtD
Metolazone—Gastrointestinal pain—Topotecan—cervical cancer	7.5e-05	0.0206	CcSEcCtD
Metolazone—Urticaria—Topotecan—cervical cancer	7.28e-05	0.02	CcSEcCtD
Metolazone—Abdominal pain—Topotecan—cervical cancer	7.25e-05	0.0199	CcSEcCtD
Metolazone—CA7—Metabolism—MTHFR—cervical cancer	7.22e-05	0.00166	CbGpPWpGaD
Metolazone—CA5B—Metabolism—MTHFR—cervical cancer	7.22e-05	0.00166	CbGpPWpGaD
Metolazone—CA9—Cellular responses to stress—TP53—cervical cancer	6.79e-05	0.00156	CbGpPWpGaD
Metolazone—Hypersensitivity—Topotecan—cervical cancer	6.75e-05	0.0185	CcSEcCtD
Metolazone—CA12—Metabolism—MTHFR—cervical cancer	6.69e-05	0.00154	CbGpPWpGaD
Metolazone—Asthenia—Topotecan—cervical cancer	6.58e-05	0.018	CcSEcCtD
Metolazone—Pruritus—Topotecan—cervical cancer	6.49e-05	0.0178	CcSEcCtD
Metolazone—Diarrhoea—Topotecan—cervical cancer	6.27e-05	0.0172	CcSEcCtD
Metolazone—Dizziness—Topotecan—cervical cancer	6.06e-05	0.0166	CcSEcCtD
Metolazone—Vomiting—Topotecan—cervical cancer	5.83e-05	0.016	CcSEcCtD
Metolazone—Rash—Topotecan—cervical cancer	5.78e-05	0.0159	CcSEcCtD
Metolazone—Dermatitis—Topotecan—cervical cancer	5.77e-05	0.0158	CcSEcCtD
Metolazone—Headache—Topotecan—cervical cancer	5.74e-05	0.0158	CcSEcCtD
Metolazone—Nausea—Topotecan—cervical cancer	5.44e-05	0.0149	CcSEcCtD
Metolazone—CA4—Metabolism—MTHFR—cervical cancer	5.33e-05	0.00123	CbGpPWpGaD
Metolazone—CA9—Metabolism—MTHFR—cervical cancer	4.31e-05	0.000991	CbGpPWpGaD
